Citations

Mayo Clinic

Showing 10 of 108602 citations.

Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic model
Shimizu, Yoshiko, Furuya, Hideki , Tamashiro, Paulette M, Iino, Kayoko, Chan, Owen , Goodison, Steve , Hokutan, Kanani , Peres, Rafael , Loo, Lenora W. M. , Naing, Aung , Chong, Clayton, Rosser, Charles J. , Kawamori, Toshihiko, Furuya, Hideki , Pagano, Ian , Hernandez, Brenda Y.

Carcinogenesis | September 7, 2017 | Volume: 39 | Issue: 1 | Pages: 47-55

10.1093/carcin/bgx097 | PMID 28968647 Get It

Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta‐analysis
Zhu, Andrew X. , Farah, Wigdan , Almasri, Jehad , Zaiem, Feras, Murad, M. Hassan , Mohammed, Khaled , Murad, Mohammad Hassan, Murad, M Hassan , Finn, Richard S. , Prokop, Larry J. , Farah, Wigdan

Hepatology | September 7, 2017 | Volume: 67 | Issue: 1 | Pages: 422-435

10.1002/hep.29486 | PMID 28881497 Get It

Hepatocellular carcinoma (HCC) is a complex disease most commonly arising in the background of chronic liver disease. In the past two decades, there has been a significant increase in our understanding of both the clinical and molecular heterogeneity of HCC. There has been a robust increase in clinical trial activity in patients with poor prognostic factors, such as macrovascular invasion and extrahepatic spread (EHS). We aimed to synthesize the evidence for the treatment of patients with advanced HCC based on these baseline characteristics, including patients with both Child‐Pugh (CP) scores of A and B. A comprehensive search of several databases from each database inception to February 15, 2016 any language was conducted. We included 14 studies (three randomized controlled studies [RCTs] and 11 observational studies). We included studies that compared sorafenib, transarterial bland embolization/transarterial chemoembolization, yttrium‐90/radiation therapy, ablation (or combination), and no therapy. Two RCTs comparing sorafenib to best supportive care demonstrated a consistent improvement in overall survival (OS) for patients with advanced HCC and metastatic vascular invasion (MVI) and/or EHS and CP A liver disease (hazard ratio, 0.66 [95% confidence interval, 0.51‐0.87]; I 2 = 0%). Several observational studies evaluated locoregional therapies alone or in combination with other treatments and were limited by very‐low‐quality of evidence. This was true for both patients with EHS and MVI. Conclusion : In patients with advanced HCC and CP A liver function, sorafenib is the only treatment that has been shown to improve OS in randomized studies. High‐quality data supporting the use of other treatment modalities in this setting, or in the setting of patients with less compensated (CP B) liver disease, are lacking. (H epatology 2018;67:422‐435)
Saddle nose deformity and septal perforation in granulomatosis with polyangiitis
Coordes, Annekatrin , Loose, Sylva, Hofmann, VM, Menger, Dirk Jan , Albers, Andreas E. , Coordes, A , Albers, A E , Hamilton, Garun S. , Riedel, Frank

Clinical Otolaryngology | September 7, 2017 | Volume: 43 | Issue: 1 | Pages: 291-299

10.1111/coa.12977 | PMID 28881107 Get It

BackgroundPatients who have granulomatosis with polyangiitis (GPA, syn. M. Wegener) often develop an external nose deformity which may have devastating psychological effects. Therefore, reconstruction of nasal deformities by rhinoplasty may become necessary to achieve a normal appearance.Objective of reviewThe aim of this systematic review was to investigate the efficacy and safety of surgical reconstruction in external nasal deformities and septal perforation in GPA patients.Search strategyA systematic literature search with defined search terms was performed for scientific articles archived in the MEDLINE‐Database up to 10 June 2016 (PubMed Advanced MEDLINE Search), describing management of cases or case series in GPA patients with saddle nose deformity and/or septal perforation.ResultsEleven of 614 publications met the criteria for this analysis including 41 GPA patients undergoing external nasal reconstruction and/or septal reconstruction with a median follow‐up of 2.6 years. Overall, saddle nose reconstruction in GPA patients is safe even if an increased rate of revision surgery has to be expected compared with individuals without GPA undergoing septorhinoplasty. Most implanted grafts were autografts of calvarial bone or costal cartilage. For septal perforation reconstruction, few studies were available. Therefore, based on the available data for surgical outcomes, it is impossible to make evidence‐based recommendations. All included GPA patients had minimal or no local disease at the time of reconstructive surgery. Therefore, the relationship between disease activity and its impact on surgical outcomes remains unanswered. The potential impact of immune‐modulating medications on increased complication rates and the impact of prophylactic antibiotics are unknown.ConclusionsThis study systematically reviews the efficacy and safety of surgical reconstruction of external nasal deformities in GPA patients for the first time. Saddle nose reconstruction in GPA patients with minimal or no local disease is a safe procedure despite an increased rate of revision surgery. Further research is required regarding the impact of antibiotic prophylaxis, immune‐modulating therapy, long‐term outcomes and functional outcomes measured with subjective and objective parameters.
Checking in: T cells against multiple myeloma
Kumar, Shaji , Kumar, Shaji K

Blood | September 7, 2017 | Volume: 130 | Issue: 10 | Pages: 1175-1176

10.1182/blood-2017-05-783647 | PMID 28882832 Get It

Evaluation of feasibility of 1.5 Tesla prostate MRI using body coil RF transmit in a patient with an implanted vagus nerve stimulator
Favazza, Christopher , Edmonson, Heidi A. , Shu, Yunhong , Felmlee, Joel P. , Watson, Robert E. , Gorny, Krzysztof R. , Favazza, Christopher P, Ma, Chi , Ma, Chi

Medical Physics | September 7, 2017 | Volume: 44 | Issue: 11 | Pages: 5749-5754

10.1002/mp.12567 | PMID 28880381 Get It

PurposeTo assess risks of RF‐heating of a vagus nerve stimulator (VNS) during 1.5 T prostate MRI using body coil transmit and to compare these risks with those associated with MRI head exams using a transmit/receive head coil.MethodsSpatial distributions of radio‐frequency (RF) B1 fields generated by transmit/receive (T/R) body and head coils were empirically assessed along the long axis of a 1.5 T MRI scanner bore. Measurements were obtained along the center axis of the scanner and laterally offset by 15 cm (body coil) and 7 cm (head coil). RF‐field measurements were supplemented with direct measurements of RF‐heating of 15 cm long copper wires affixed to and submerged in the “neck” region of the gelled saline‐filled (sodium chloride and polyacrylic acid) “head‐and‐torso” phantom. Temperature elevations at the lead tips were measured using fiber‐optic thermometers with the phantom positioned at systematically increased distances from the scanner isocenter.ResultsB1 field measurements demonstrated greater than 10 dB reduction in RF power at distances beyond 28 cm and 24 cm from isocenter for body and head coil, respectively. Moreover, RF power from body coil transmit at distances greater than 32 cm from isocenter was found to be lower than from the RF power from head coil transmit measured at locations adjacent to the coil array at its opening. Correspondingly, maximum temperature elevations at the tips of the copper wires decreased with increasing distance from isocenter — from 7.4°C at 0 cm to no appreciable heating at locations beyond 40 cm.ConclusionsFor the particular scanner model evaluated in this study, positioning an implanted VNS farther than 32 cm from isocenter (configuration achievable for prostate exams) can reduce risks of RF‐heating resulting from the body coil transmit to those associated with using a T/R head coil.
Cold platelets for trauma‐associated bleeding: regulatory approval, accreditation approval, and practice implementation—just the “tip of the iceberg”
Stubbs, James R. , Tran, Sheryl A., Emery, Richard L., Hammel, Scott A., Haugen, De Anna L., Zielinski, Martin D. , Zietlow, Scott P., Jenkins, Donald H.

Transfusion | September 7, 2017 | Volume: 57 | Issue: 12 | Pages: 2836-2844

10.1111/trf.14303 | PMID 28880362 Get It

BACKGROUNDLaboratory and clinical evidence suggest that cold‐stored platelets (CS‐PLTs) might be preferable to room temperature platelets (RT‐PLTs) for active bleeding. Ease of prehospital use plus potential hemostatic superiority led our facility to pursue approval of CS‐PLTs for actively bleeding trauma patients.STUDY DESIGN AND METHODSFrom November 18, 2013, through October 8, 2015, correspondence was exchanged between our facility, the AABB, and the US Food and Drug Administration (FDA). An initial AABB variance request was for 5‐day CS‐PLTs without agitation. The AABB deferred its decision pending FDA approval to use our platelet (PLT) bags for CS‐PLTs. On March 27, 2015, the FDA approved 3‐day CS‐PLTs without agitation. On October 8, 2015, the AABB approved 3‐day CS‐PLTs without agitation and without bacterial testing for actively bleeding trauma patients. Our facility's goal is to carry CS‐PLTs on air ambulances.RESULTSCS‐PLTs have been used for trauma patients at our facility since October 2015. As of August 2016, a total of 21 (19.1%) of 119 CS‐PLTs have been transfused. The short 3‐day storage period combined with the formation of clots in plasma‐rich CS‐PLTs during storage have been the major causes of a high (80.9%) discard rate.CONCLUSIONIn the future, pathogen‐reduced (PR), PLT additive solution (PAS) CS‐PLTs seem more practical due to low risks of bacterial contamination and storage‐related clotting. This should make longer storage of CS‐PLTs feasible (e.g., 10 days or more). With a longer shelf life, PR PAS CS‐PLTs could potentially be used in a wider range of patient populations.
Indeterminate dendritic cell neoplasm of the skin: A 2‐case report and review of the literature
Horna, Pedro , Shao, Haipeng , Idrees, Afshan, Glass, L. Frank, Torres‐Cabala, Carlos A. , Torres-Cabala, Carlos , Horna, Pedro

Journal of Cutaneous Pathology | September 7, 2017 | Volume: 44 | Issue: 11 | Pages: 958-963

10.1111/cup.13017 | PMID 28880462 Get It

Indeterminate dendritic cell neoplasm (IDCN) is an exceedingly rare and mostly cutaneous histiocytosis, frequently associated with other hematopoietic malignancies. We report 2 cases of multilesional cutaneous IDCN. A 55‐year‐old male with no associated malignancy and complete response to ultraviolet phototherapy; and a 72‐year‐old male with chronic myelomonocytic leukemia (CMML). Both cases showed histiocytoid cytology, positivity for CD1a and no expression of langerin or BRAFV600E. With our patients, the literature describes 79 cases of IDCNs, including 65 (82%) with only skin involvement, 7 cases (9%) with involvement of skin and a second site, 5 cases (6%) involving lymph nodes only, 1 splenic lesion and 1 systemic disease. Seventeen cases (22%) were associated with other hematopoietic malignancies, most commonly CMML (6 cases), follicular lymphoma (4 cases) and acute myeloid leukemia (3 cases). All IDCNs associated with myeloid malignancies were limited to the skin, while most cases associated with lymphoma were limited to lymph nodes. Reported responses of cutaneous lesions to ultraviolet phototherapy are encouraging, while systemic chemotherapy is appropriate for clinically aggressive cases and treatment of associated malignancies. Recognition of the clinico‐morphologic spectrum of IDCNs should prevent misdiagnoses and prompt investigation of possible associated neoplasms.
Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011
Enninga, Elizabeth Ann L. , Moser, Justin C. , Weaver, Amy L. , Brewer, Jerry D., Leontovich, Alexey A. , Shuster, Lynne T., Kottschade, Lisa A. , Olariu, Ariadna, Mansfield, Aaron S. , Dronca, Roxana , Dronca, Roxana S., Mansfield, Aaron S , Enninga, Elizabeth Ann L , Markovic, Svetomir N. , Hieken, Tina J.

Cancer Medicine | September 7, 2017 | Volume: 6 | Issue: 10 | Pages: 2203-2212

10.1002/cam4.1152 | PMID 28879661 Get It

AbstractWomen diagnosed with cutaneous melanoma have a survival advantage compared to men, which has been hypothesized to be due to difference in behavior and/or biology (sex hormones). It remains controversial whether this advantage is dependent on age or stage of disease. We sought to compare melanoma‐specific survival between females in pre, peri, and postmenopausal age groups to males in the same age group, adjusting for stage of disease. This is a retrospective population‐based cohort study using the Surveillance, Epidemiology, and End Results (SEER) database. Patients diagnosed from 1 January 1992 through 31 January 2011 with primary invasive cutaneous melanoma were included in our cohort. Melanoma‐specific survival was the main outcome studied. Of the 106,511 subjects that were included, 45% were female. Females in all age groups (18–45, 46–54, and ≥55) with localized and regional disease, were less likely to die from melanoma compared to males in the same age group. Among patients with localized and regional disease, the relative risk of death due to melanoma increased with advancing age at diagnosis; this increase was more pronounced among females than males. In contrast, we observed no female survival advantage among patients with distant disease and no effect of age on relative risk of death from melanoma. Females with localized and regional melanoma have a decreased risk of death compared to males within all age groups. Our data show no differences in survival between men and women with metastatic melanoma, indicating that the influence of sex on survival is limited to early stage disease but not confined to pre or perimenopausal age groups.
A Reconfigurable Multiplanar In Vitro Simulator for Real-Time Absolute Motion With External and Musculotendon Forces
Green, Joshua T. , Hale, Rena F. , Hausselle, Jérôme, Gonzalez, Roger V.

Journal of Biomechanical Engineering | September 7, 2017 | Volume: 139 | Issue: 12 | Pages: No page available

10.1115/1.4037853 | PMID 28877307 Get It

Advancements in computational musculoskeletal biomechanics are constrained by a lack of experimental measurement under real-time physiological loading conditions. This paper presents the design, configuration, capabilities, accuracy, and repeatability of The University of Texas at El Paso Joint Load Simulator (UTJLS) by testing four cadaver knee specimens with 47 real-time tests including heel and toe squat maneuvers with and without musculotendon forces. The UTJLS is a musculoskeletal simulator consisting of two robotic manipulators and eight musculotendon actuators. Sensors include eight tension load cells, two force/torque systems, nine absolute encoders, and eight incremental encoders. A custom control system determines command output for position, force, and hybrid control and collects data at 2000 Hz. Controller configuration performed forward-dynamic control for all knee degrees-of-freedom (DOFs) except knee flexion. Actuator placement and specimen potting techniques uniquely replicate muscle paths. Accuracy and repeatability standard deviations across specimen during squat simulations were equal or less than 8 N and 5 N for musculotendon actuators, 30 N and 13 N for ground reaction forces (GRFs), and 4.4 N·m and 1.9 N·m for ground reaction moments. The UTJLS is the first of its design type. Controller flexibility and physical design support axis constraints to match traditional testing rigs, absolute motion, and synchronous real-time simulation of multiplanar kinematics, GRFs, and musculotendon forces. System DOFs, range of motion, and speed support future testing of faster maneuvers, various joints, and kinetic chains of two connected joints.
The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma
Moigne, Ronan Le , Aftab, Blake T. , Djakovic, Stevan, Dhimolea, Eugen , Murnane, Megan, King, Emily M. , Soriano, Ferdie, Menon, Mary-Kamala, Wu, Zhi , Lee, Grace J. , Lam, Christine , Rice, Julie , Wang, Jinhai , Chesi, Marta , Bergsagel, P. Leif , Kraus, Marianne , Driessen, Christoph , Soly, Szerenke Kiss Von, Yakes, F. Michael, Wustrow, David J., Shawver, Laura K. , Zhou, Han-Jie , Wolf, Jeffrey L. , Mitsiades, Constantine S. , Rolfe, Mark , Bergsagel, P. Leif , Junior, Eduardo Alves do Valle , Wong, Stephen T.C. , Yao, Bing , Wiita, Arun P. , Martin, Thomas G. , Anderson, Daniel J.

Molecular Cancer Therapeutics | September 6, 2017 | Volume: 16 | Issue: 11 | Pages: 2375-2386

10.1158/1535-7163.mct-17-0233 | PMID 28878026 Get It

Abstract Inhibition of the AAA ATPase, p97, was recently shown to be a novel method for targeting the ubiquitin proteasome system, and CB-5083, a first-in-class inhibitor of p97, has demonstrated broad antitumor activity in a range of both hematologic and solid tumor models. Here, we show that CB-5083 has robust activity against multiple myeloma cell lines and a number of in vivo multiple myeloma models. Treatment with CB-5083 is associated with accumulation of ubiquitinated proteins, induction of the unfolded protein response, and apoptosis. CB-5083 decreases viability in multiple myeloma cell lines and patient-derived multiple myeloma cells, including those with background proteasome inhibitor (PI) resistance. CB-5083 has a unique mechanism of action that combines well with PIs, which is likely owing to the p97-dependent retro-translocation of the transcription factor, Nrf1, which transcribes proteasome subunit genes following exposure to a PI. In vivo studies using clinically relevant multiple myeloma models demonstrate that single-agent CB-5083 inhibits tumor growth and combines well with multiple myeloma standard-of-care agents. Our preclinical data demonstrate the efficacy of CB-5083 in several multiple myeloma disease models and provide the rationale for clinical evaluation as monotherapy and in combination in multiple myeloma. Mol Cancer Ther; 16(11); 2375–86. ©2017 AACR.